Through joint development with Bacchus Bio innovation, JSR will develop and produce raw materials for its key biomass products utilizing synthetic biology.
Ajinomoto Co. has reached an agreement with JSR to collaborate on the global expansion of its biopharmaceutical culture media business, adding new high-performance media developed by JSR, to Ajinom...
JSR Corporation announced today that it has entered into a facility usage agreement with AuB, a company engaged in the study of intestinal microbiota in athletes.
JSR Corporation announced today that it has concluded a facility use agreement with KINS Co., Ltd. (KINS), a company with a database of human microbiome.
JSR Life Sciences, LLC is pleased to announce that JSR Corporation and Asahi Kasei Medical have entered into a co-promotion agreement for bioprocess products and materials that initiated sales coll...
JSR Life Sciences that the JSR Corporation has finalized the acquisition of all outstanding shares in MBL. As a result, MBL is a wholly owned subsidiary and affiliate of the JSR Life Sciences famil...
The development will be based on PeptiDream’s proprietary drug discovery platform, PDPS (Peptide Discovery Platform System), and JSR’s extensive knowledge of affinity separation technology.
Through this collaboration, Aspect’s proprietary Lab-on-a-Printer™ 3D bioprinting platform and JSR’s advanced materials technology will be used to develop vascularized human liver lobules.
JSR will be providing the equity capital for OPM Asia that will enable the establishment of a world-class biomedical manufacturing and market development operation.
JSR will develop technologies related to maintaining homeostasis of gut microbiota and in vitro diagnostic products through the JSR-Keio University Medical and Chemical Innovation Center (JKiC).
1 of 2
Receive JSR Life Sciences news on your RSS reader.
